A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients

This study has been completed.

First Received on March 27, 2007. Last Updated on January 27, 2011 History of Changes

Sponsor:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00453778

Purpose

Investigate if asthmatics treated with FLIXOTIDE (FP) 500 mcg BID during 14 days get reduced bronchial reactivity after inhalation of Leukotriene D4. Two 14 days treatment periods where patients received FP 500 MCG BID and placebo. Washout at least 21 days between treatments. Bronchial challenge with methacholine and Leukotriene D4 were performed before the start of each treatment period and on treatment days 13 and 14 respectively.

Condition	Intervention	Phase
Asthma Mild Asthma	Drug: FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	A Study to Investigate the Effect of Inhaled Fluticasone Propionate on the Bronchial Responsiveness to Leukotriene D4 in Asthmatics Patients

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Fluticasone propionate Fluticasone

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

LTD4 PC20

Secondary Outcome Measures:

Shift in methacholine PD20

Estimated Enrollment:	14
Study Start Date:	November 2002

Intervention Details:

Other Name: FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion:

Diagnosed history of asthma
Non smoker last two years
< 5 pack years
FEV1 >70% of predicted
Mild and stable asthma
Only using short acting b2-agonist as rescue for the last 4 weeks
Have a history of atopy.

Exclusion:

Any significant respiratory disease, other than asthma
Subjects with seasonal asthma may not be included if they are in their season
Use of oral or inhaled glucocorticosteroid for the last 3 months and long-acting or oral b2-agonists, anticholinergic bronchodilators, cromones, antihistamines, theophyllines and antileukotrienes within two weeks
Upper or lower RTI within 6 weeks
Evidence of any disease that in the investigators mind would affect the results of the study
Participating in another study within 4 weeks
Females who are pregnant, intend to be or who are lactating
Methacholine PD20 > 454mcg
Negative scin prick test

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453778

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	E.D. Derilus; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier:	NCT00453778 History of Changes
Other Study ID Numbers:	FMS40273
Study First Received:	March 27, 2007
Last Updated:	January 27, 2011
Health Authority:	Sweden: Medical Products Agency

Keywords provided by GlaxoSmithKline:

mild asthma
FLIXOTIDE
methacholine
bronchial challenge
leukotriene D4

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Bronchodilator Agents

Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Dermatologic Agents
Anti-Allergic Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on February 13, 2012